Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse

References

• Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA.1989;86:10024–10028.
   PubMed Web of Science ®Google Scholar
• Maus MV, Grupp SA, Porter DL, et al. Antibody modified T cells: CARs take the front seat for hematologic malignancies. Blood. 2014;123:2625–2635.
   PubMed Web of Science ®Google Scholar
• Gill S. Planes, trains, and automobiles: perspectives on CAR T cells and other cellular therapies for hematologic malignancies. Curr Hematol Malig Rep. 2016;11:318–325.
   PubMed Web of Science ®Google Scholar
• Maude SL, Teachey DT, Porter DL, et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125:4017–4023.
   PubMed Web of Science ®Google Scholar
• Smith AJ, Oertle J, Warren D, et al. Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: summary and perspective. J Cell Immunother. 2016;2:59–68.
   Google Scholar
• Almåsbak H, Aarvak T, Vemuri MC. CAR T cell therapy: a game changer in cancer treatment. J Immunol Res. 2016;2016:5474602.
   PubMed Web of Science ®Google Scholar
• Johnson LA, June CH. Driving gene-engineered T cell immunotherapy of cancer. Cell Res. 2017;27:38–58.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–1517.
   PubMed Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet. 2015;385:517–528.
   PubMed Web of Science ®Google Scholar
• Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25.
   PubMed Web of Science ®Google Scholar
• Maude SL, Pulsipher MA, Boyer MW, et al. Efficacy and safety of CTL019 in the first US phase II multicenter trial in pediatric relapsed/refractory acute lymphoblastic leukemia: results of an interim analysis. Blood. 2016;128:2801.
   Web of Science ®Google Scholar
• Grupp SA, Laetsch TW, Buechner J, et al. Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL). Blood. 2016;128:221.
   Web of Science ®Google Scholar
• Locke FL, Neelapu SS, Bartlett NL, et al. Phase 1 results of ZUMA-1: a multicenter study of KTE-C19 anti-CD19 CAR T cell therapy in refractory aggressive lymphoma. Mol Ther. 2017;25:285–295.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Somerville RPT, Lu T, et al. Lymphoma remissions caused by Anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels. J Clin Oncol. 2017;35:1803–1813.
   PubMed Web of Science ®Google Scholar
• Porter DL, Hwang W-T, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7:303ra139.
   PubMed Web of Science ®Google Scholar
• Golubovskaya V, Wu L. Different subsets of T cells, memory, effector functions, and CAR-T immunotherapy. Cancers. 2016;8:36.
   PubMed Web of Science ®Google Scholar
• Sommermeyer D, Hudecek M, Kosasih PL, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30:492–500.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hanafi L-A, Berger C, et al. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8+/CD4+ CD19-specific chimeric antigen receptor–modified T cells. Sci Transl Med. 2016;8:355ra116–355ra116.
   PubMed Web of Science ®Google Scholar
• Gee AP. Manufacturing genetically modified T cells for clinical trials. Cancer Gene Ther. 2015;22:67–71.
   PubMed Web of Science ®Google Scholar
• Kalaitsidou M, Kueberuwa G, Schutt A, et al. CAR T-cell therapy: toxicity and the relevance of preclinical models. Immunotherapy. 2015;7:487–497.
   PubMed Web of Science ®Google Scholar
• Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127:3321–3330.
   PubMed Web of Science ®Google Scholar
• Bonifant CL, Jackson HJ, Brentjens RJ, et al. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics. 2016;3:16011
   PubMed Web of Science ®Google Scholar
• Maude SL, Barrett D, Teachey DT, et al. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20:119–122.
   PubMed Web of Science ®Google Scholar
• Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–195.
   PubMed Web of Science ®Google Scholar
• Kranick S, Phan G, Kochenderfer J, et al. Aphasia as a complication of CD19-targeted chimeric antigen receptor immunotherapy (S52.006). Neurology. 2015;82(10 Supplement):S52.006.
   Google Scholar
• Benjamin JE, Stein AS. The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia. Ther Adv Hematol. 2016;7:142–156.
   PubMed Web of Science ®Google Scholar
• Hu Y, Sun J, Wu Z, et al. Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J Hematol Oncol. 2016;9:70.
   PubMed Web of Science ®Google Scholar
• Shalabi H, Wolters PL, Martin S, et al. A prospective evaluation of neurocognitive function and neurologic symptoms in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) undergoing anti-CD22 chimeric antigen receptor therapy. 58th ASH Annual Meeting and Exposition; San Diego (CA); 2016.
   Google Scholar
• Cohen AD, Garfall AL, Stadtmauer EA, et al. B-cell maturation antigen (BCMA)-specific chimeric antigen receptor T cells (CART-BCMA) for multiple myeloma (MM): initial safety and efficacy from a phase I study. Blood. 2016;128:1147.
   Web of Science ®Google Scholar
• Bhoj VG, Arhontoulis D, Wertheim G, et al. Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood. 2016;128:360–370.
   PubMed Web of Science ®Google Scholar
• Grupp SA. Advances in T-cell therapy for ALL. Best Pract Res Clin Haematol. 2014;27:222–228.
   PubMed Web of Science ®Google Scholar
• Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1:36.
   PubMedGoogle Scholar
• Otero DC, Anzelon AN, Rickert RC. CD19 function in early and late B cell development: I. maintenance of follicular and marginal zone B cells requires CD19-dependent survival signals. J Immunol. 2003;170:73–83.
   PubMed Web of Science ®Google Scholar
• Weiland J, Pal D, Case M, et al. BCP-ALL blasts are not dependent on CD19 expression for leukaemic maintenance. Leukemia. 2016;30:1920–1923.
   PubMed Web of Science ®Google Scholar
• Sotillo E, Barrett DM, Black KL, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282–1295.
   PubMed Web of Science ®Google Scholar
• Ruella M, Barrett DM, Kenderian SS, et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016;126:3814–3826.
   PubMed Web of Science ®Google Scholar
• Zhang W-Y, Wang Y, Guo Y-l, et al. Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report. Signal Transduct Targeted Ther. 2016;1:16002.
   PubMed Web of Science ®Google Scholar
• Shah NN, Stevenson MS, Yuan CM, et al. Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr Blood Cancer. 2015;62:964–969.
   PubMed Web of Science ®Google Scholar
• Broughton SE, Dhagat U, Hercus TR, et al. The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling. Immunol Rev. 2012;250:277–302.
   PubMed Web of Science ®Google Scholar
• Hara T, Miyajima A. Function and signal transduction mediated by the interleukin 3 receptor system in hematopoiesis. Stem Cells. 1996;14:605–618.
   PubMed Web of Science ®Google Scholar
• Testa U, Pelosi E, Frankel A. CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies. Biomark Res. 2014;2:4.
   PubMedGoogle Scholar
• Ehninger A, Kramer M, Röllig C, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014;4:e218.
   PubMed Web of Science ®Google Scholar
• ten Cate B, de Bruyn M, Wei Y, et al. Targeted elimination of leukemia stem cells; a new therapeutic approach in hemato-oncology. Curr Drug Targets. 2010;11:95–110.
   PubMed Web of Science ®Google Scholar
• Testa U, Fossati C, Samoggia P, et al. Expression of growth factor receptors in unilineage differentiation culture of purified hematopoietic progenitors. Blood. 1996;88:3391–3406.
   PubMed Web of Science ®Google Scholar
• Li LJ, Tao JL, Fu R, et al. Increased CD34 + CD38 -CD123 + cells in myelodysplastic syndrome displaying malignant features similar to those in AML. Int J Hematol. 2014;100:60–69.
   PubMed Web of Science ®Google Scholar
• Jordan CT, Upchurch D, Szilvassy SJ, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14:1777–1784.
   PubMed Web of Science ®Google Scholar
• Gill S, Tasian SK, Ruella M, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014;123:2343–2354.
   PubMed Web of Science ®Google Scholar
• Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105–111.
   PubMed Web of Science ®Google Scholar
• Testa U, Riccioni R, Militi S, et al. Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002;100:2980–2988.
   PubMed Web of Science ®Google Scholar
• Vergez F, Green AS, Tamburini J, et al. High levels of CD34 + CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica. 2011;96:1792–1798.
   PubMed Web of Science ®Google Scholar
• He SZ, Busfield S, Ritchie DS, et al. A phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia. Leuk Lymphoma. 2015;56:1406–1415.
   PubMed Web of Science ®Google Scholar
• FitzGerald DJ. Targeted diphtheria toxin to treat BPDCN. Blood. 2014;124:310–312.
   PubMed Web of Science ®Google Scholar
• Sweet KL, Pemmaraju N, Lane AA, et al. Lead-in stage results of a pivotal trial of SL-401, an interleukin-3 receptor (IL-3R) targeting biologic, in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) or acute myeloid leukemia (AML). Blood. 2015;126:3795.
   Web of Science ®Google Scholar
• Angelot-Delettre F, Roggy A, Frankel AE, et al. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent. Haematologica. 2015;100:223–230.
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Lane AA, Sweet KL, et al. Results from phase 2 trial ongoing expansion stage of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). American Society of Hematology, 58th Annual Meeting and Exposition; San Diego, (CA); 2016.
   Google Scholar
• Thokala R, Olivares S, Mi T, et al. Redirecting specificity of T cells using the sleeping beauty system to express chimeric antigen receptors by mix-and-matching of VL and VH domains targeting CD123+ tumors. PLoS One. 2016;11:e0159477.
   PubMed Web of Science ®Google Scholar
• Tettamanti S, Marin V, Pizzitola I, et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol. 2013;161:389–401.
   PubMed Web of Science ®Google Scholar
• Mardiros A, Dos Santos C, McDonald T, et al. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia. Blood. 2013;122:3138–3148.
   PubMed Web of Science ®Google Scholar
• Tasian SK, Kenderian SS, Shen F, et al. Optimized depletion of chimeric antigen receptor T-cells in murine xenograft models of human acute myeloid leukemia. Blood. 2017;129:2395–2407.
   PubMed Web of Science ®Google Scholar
• Cai T, Galetto R, Gouble A, et al. Pre-clinical studies of anti-CD123 CAR-T cells for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood. 2016;128:4039.
   Web of Science ®Google Scholar
• Tasian SK, Kenderian SS, Shen F, et al. Efficient termination of CD123-redirected chimeric antigen receptor T cells for acute myeloid leukemia to mitigate toxicity. Blood. 2015;126:565.
   Web of Science ®Google Scholar
• Marin V, Pizzitola I, Biondi A, et al. Comparison of dfferent suicide gene strategies for the safety improvement of genetically manipulated T cells. Blood. 2010;116:3753.
   Web of Science ®Google Scholar
• Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Hanafi L-A, Berger C, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016;126:2123–2138.
   PubMed Web of Science ®Google Scholar
• Chong EA, Melenhorst JJ, Lacey SF, et al. PD-1 blockade modulates chimeric antigen receptor (CAR)-modified T cells: refueling the CAR. Blood. 2017;129:1039–1041.
   PubMed Web of Science ®Google Scholar
• Ruella M, Kenderian SS, Shestova O, et al. The addition of the BTK inhibitor ibrutinib to anti-CD19 Chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma. Clin Cancer Res. 2016;22:2684–2696.
   PubMed Web of Science ®Google Scholar
• Fraietta JA, Beckwith KA, Patel PR, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127:1117–1127.
   PubMed Web of Science ®Google Scholar
• Turtle CJ, Berger C, Sommermeyer D, et al. Anti-CD19 chimeric antigen receptor-modified T cell therapy for B cell non-Hodgkin lymphoma and chronic lymphocytic leukemia: fludarabine and cyclophosphamide lymphodepletion improves in vivo expansion and persistence of CAR-T cells and clinical outcomes. Blood. 2015;126:184.
   Web of Science ®Google Scholar
• Kipps TJ, Stevenson FK, Wu CJ, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017;3:16096.
   PubMed Web of Science ®Google Scholar
• Delgoffe GM. Filling the tank: keeping antitumor T cells metabolically fit for the long haul. Cancer Immunol Res. 2016;4:1001–1006.
   PubMed Web of Science ®Google Scholar